What are the guideline‑recommended treatment options for an adult with community‑acquired pneumonia, including outpatient, non‑ICU inpatient, and ICU management?

Community-Acquired Pneumonia Management Guidelines

Outpatient Treatment

For previously healthy adults without comorbidities, amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line therapy, providing superior pneumococcal coverage against 90–95% of Streptococcus pneumoniae isolates including many penicillin-resistant strains. 1

• Doxycycline 100 mg orally twice daily serves as an acceptable alternative when amoxicillin is contraindicated, offering coverage of both typical and atypical organisms. 1
• Macrolides (azithromycin 500 mg day 1 then 250 mg daily, or clarithromycin 500 mg twice daily) should only be used in areas where pneumococcal macrolide resistance is documented <25%; in most U.S. regions resistance is 20–30%, making macrolide monotherapy unsafe as first-line therapy. 1, 2

For adults with comorbidities (COPD, diabetes, chronic heart/liver/renal disease, malignancy, or recent antibiotic use within 90 days), combination therapy is required: 1

• Option 1: β-lactam (amoxicillin-clavulanate 875/125 mg twice daily, cefpodoxime, or cefuroxime) plus macrolide (azithromycin or clarithromycin) or doxycycline 100 mg twice daily. 1
• Option 2: Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily), reserved for patients with β-lactam allergy or when combination therapy is contraindicated due to FDA safety warnings. 1

Hospitalized Non-ICU Patients

Two equally effective regimens exist with strong recommendations and high-quality evidence: 1

• Preferred regimen: Ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV or orally daily, providing comprehensive coverage for typical pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 1, 3
• Alternative: Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily), which systematic reviews show has fewer clinical failures and treatment discontinuations compared to β-lactam/macrolide combinations. 1
• For penicillin-allergic patients, respiratory fluoroquinolone is the preferred alternative. 1

Critical timing: Administer the first antibiotic dose in the emergency department immediately upon diagnosis; delays beyond 8 hours increase 30-day mortality by 20–30%. 1, 4

ICU-Level Severe CAP

Combination therapy is mandatory for all ICU patients; β-lactam monotherapy is associated with higher mortality in critically ill patients with bacteremic pneumococcal pneumonia. 1, 5

• Preferred ICU regimen: Ceftriaxone 2 g IV daily (or cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours) plus azithromycin 500 mg IV daily or respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily). 1
• For penicillin-allergic ICU patients, use aztreonam 2 g IV every 8 hours plus respiratory fluoroquinolone. 1

Special Pathogen Coverage (Only When Risk Factors Present)

Pseudomonas aeruginosa Coverage

Add antipseudomonal therapy only when specific risk factors are present: 1

• Structural lung disease (bronchiectasis, cystic fibrosis)
• Recent hospitalization with IV antibiotics within 90 days
• Prior respiratory isolation of P. aeruginosa
• Chronic broad-spectrum antibiotic exposure (≥7 days in past month)

Regimen: Antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g IV every 6 hours or cefepime 2 g IV every 8 hours) plus ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily plus aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily) for dual antipseudomonal coverage. 1

MRSA Coverage

Add MRSA therapy only when risk factors are present: 1

• Prior MRSA infection/colonization
• Recent hospitalization with IV antibiotics
• Post-influenza pneumonia
• Cavitary infiltrates on imaging

Regimen: Vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base CAP regimen. 1

Duration of Therapy

Treat for a minimum of 5 days and continue until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 3

• Typical duration for uncomplicated CAP: 5–7 days. 1, 2
• Extended duration (14–21 days) required only for Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli. 1

Transition from IV to Oral Therapy

Switch to oral antibiotics when all stability criteria are met (typically by hospital day 2–3): 1

• Hemodynamically stable (SBP ≥90 mmHg, HR ≤100 bpm)
• Clinically improving
• Afebrile for 48–72 hours
• Respiratory rate ≤24 breaths/min
• Oxygen saturation ≥90% on room air
• Able to take oral medications
• Normal GI function

Diagnostic Testing

Obtain blood cultures and sputum Gram stain/culture before initiating antibiotics in all hospitalized patients to enable pathogen-directed therapy and safe de-escalation. 1, 6

• For outpatients with mild CAP, extensive microbiological testing is not routinely required; empirical treatment should be initiated. 6, 4
• Up to 50% of CAP cases have no identifiable pathogen, reinforcing that testing should not delay antibiotic initiation. 6

Severity Assessment & Admission Criteria

Use validated severity scores (PSI or CURB-65) together with clinical judgment to determine hospitalization need: 7

• PSI classes I–III: Outpatient management appropriate
• PSI classes IV–V: Hospitalization required
• CURB-65 ≥2: Hospital admission indicated

ICU admission criteria: Any one major criterion (septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation) or ≥3 minor criteria (confusion, respiratory rate ≥30/min, SBP <90 mmHg, multilobar infiltrates, PaO₂/FiO₂ <250). 1, 7

Critical Pitfalls to Avoid

• Never use macrolide monotherapy in hospitalized patients—it fails to cover typical pathogens like S. pneumoniae and leads to treatment failure. 1
• Avoid macrolide monotherapy in outpatients when local pneumococcal macrolide resistance exceeds 25%, as this increases risk of breakthrough bacteremia. 1, 2
• Do not add broad-spectrum antipseudomonal or MRSA agents routinely—restrict to patients with documented risk factors to prevent resistance without clinical benefit. 1
• Do not delay antibiotic administration while awaiting culture results; delays beyond 8 hours significantly increase mortality. 1, 4
• Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection) and rising resistance. 1

Follow-Up & Monitoring

• Outpatient review at 48 hours (or sooner if symptoms worsen) to assess response, oral intake, and adherence. 1
• Hospitalized patients: Monitor vital signs (temperature, respiratory rate, pulse, blood pressure, oxygen saturation) at least twice daily. 1
• Routine follow-up at 6 weeks for all patients; chest radiograph only for those with persistent symptoms, abnormal physical findings, or high risk for underlying malignancy (smokers >50 years). 1